Compare LGL & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | CING |
|---|---|---|
| Founded | 1917 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 26.8M |
| IPO Year | N/A | 2021 |
| Metric | LGL | CING |
|---|---|---|
| Price | $5.70 | $4.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 8.8K | ★ 131.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,107,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.45 | $3.20 |
| 52 Week High | $9.74 | $6.01 |
| Indicator | LGL | CING |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 61.65 |
| Support Level | $5.57 | $3.85 |
| Resistance Level | $5.90 | $4.30 |
| Average True Range (ATR) | 0.20 | 0.27 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 47.98 | 81.34 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.